A few days ago, the official website of the NMPA released the drug approval certificate. The information showed on March 22, the Lenvatinib capsule developed by Hangzhou Qingyue and Shanxiang pharm...
On August 1, 2021 (the 38th) national pharmaceutical industry information annual conference was grandly opened in Jinan, Shandong Province. The conference officially released the list of the best ...
On June 24, China National Intellectual Property Administration officially announced the list of winners of the 22nd China Patent Award. Qingfeng Pharma. new method for synthesizing lacosamide won ...
On February 3, Shanghai Yangguang Pharmaceutical Purchasing Network officially released the bidding results of fourth batch of national volume based procurement. Jiangxi Shanxiang Pharmaceutical Co...
On November 4, Xinkang® Lacosamide injection, declared by Jiangxi Qingfeng Pharmaceutical Co., Ltd., was approved by NMPA and deemed to have passed the consistency evaluation. This is the first ...
On September 10, Shanghai Denovo PharmaceuticalTechnology Co., Ltd., a subsidiary of Qingfeng Pharmaceutical Group, held aTLR8 agonist DN1508052-01 Phase I clinical trial kick-off meeting at Shangh...
On August 25, 2020, our clinical research team held a GP681 clinical study kick-off meeting in Shanghai Xuhui District Central Hospital, marking that our innovative drug GP681 has officially ...
On August 30th, the high-profile "2019 China Pharmaceutical Industry Top 100 List" was grandly released in Zhuhai. Qingfeng Pharmaceutical Group was once again nominated as the 64th place among ...
The Class 4 chemical generic Sorafenib tosylate tablets (trade name: Ligesitai®) developed by Jiangxi Shanxiang Pharmaceutical Co., Ltd., a subsidiary of Qingfeng Pharmaceutical Group, were ...
The first generic of Esomeprazole Magnesium Enteric-coated Tablets was approved for marketing, which is deemed to pass consistency evaluation. A few days ago, Esomeprazole Magnesium Enteric-coated ...
On July 8, Bangkaxin® (Esomeprazole Magnesium Enteric-coated Tablets) declared by Qingfeng Pharmaceutical Group and Jiangxi Shanxiang Pharmaceutical Co., Ltd. was approved by NMPA. The successful ...
On May 12, the National Medical Products Administration (NMPA) formally approved the application of Shikang® Apixaban tablets from Jiangxi Qingfeng Pharmaceutical.
Recently, Jiangxi Qingfeng Pharmaceutical'sapplication for Apixaban tablets (acceptance number CYHS1800008) submittedunder the generic category 4 was approved, and the approval number was H20203204...
On the afternoon of April 15, Yao Zengke, Chairman of the Provincial Committee of the Chinese People's Political Consultative Conference, accompanied by Deputy Secretary of the Provincial Party ...
On the afternoon of February 25th, Liu Qi, Secretary of the Provincial Party Committee, visited Qingfeng Pharmaceutical to inspect the epidemic prevention and control and resumption of production....
On February 24, Yi Lianhong, the governor of the Provincial Party Committee and the leader of the Provincial Party Committee’s Leading Group for Response to the Epidemic, was in the provincial ...
On the morning of February 7, Li Bingjun, deputy secretary of the provincial party committee and secretary of the municipal party committee, visited our company to guide the resumption of work and ...
